Record overview
Status and phase
Status: NOT_YET_RECRUITING
Phase: PHASE2
Sponsor: Yantai Yuhuangding Hospital
Condition: Neoadjuvant Therapy, Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer
NCT07054242
A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.